Navigation Links
Researchers pinpoint genetic pathways involved in breast cancer
Date:3/3/2011

EAST LANSING, Mich. Using recent advances in genomics, researchers have uncovered a genetic pathway that affects the development of breast cancer, work that could help predict which patients are at risk of relapse for the disease.

By studying which genes are expressed or "turned on" in breast cancer, research led by Michigan State University's Eran Andrechek uncovered a role for several members of the E2F family of genes, which control cell division and growth.

Specifically, Andrechek's team found the activation of the specific gene E2F2 was associated with a higher probability of breast cancer relapse in humans. The research team, using rodent models, also found that removing the E2F2 gene significantly decreased the likelihood of a tumor.

The findings, to be published in the journal Cancer Research, are available online now.

"Genomic signatures how genes interact and via what pathways are a rapidly growing and a powerful method to analyze specific genes in the development, recurrence and spread of breast cancer," said Andrechek, an assistant professor in the MSU Department of Physiology and lead author of the paper.

After identifying which genes are being activated, physicians can tailor treatments for breast cancer and other diseases to individuals with certain genetic makeups. For example, breast cancer patients with over-expression of a gene called HER2 are currently treated with the antibody Herceptin, which specifically targets the cells over-expressing HER2.

"With personalized medicine, we can use predictions of how genes will interact, and based on that we can make better use of existing treatments that will have more of an impact," Andrechek said.

As part of the research, Andrechek and his team focused on tumors initiated by Myc, a gene that is amplified in 15 percent of all human breast cancer cases. The team then analyzed the tumors to test which pathways were critical to tumor growth, first in computer models and then in rodent models.

In addition to the discovery of E2F2's role in tumor incidence and relapse, the research also revealed the gene was critical for the development of a type of basal tumor. These tumors are similar to the so-called "triple negative tumors" in human breast cancer that are more prevalent among blacks and are much more difficult to treat.

The article can be viewed online at http://cancerres.aacrjournals.org/content/early/2011/01/18/0008-5472.CAN-10-2386.abstract. Other contributing authors included Kenichiro Fujiwara, Inez Yuwanita, and Daniel Hollern.

An extension of Andrechek's work has recently been funded by the Elsa U. Pardee Foundation a Michigan organization that has given more than $113 million in grants for cancer research to explore therapy options based on genomic profiles.

"We want to examine how we can design therapies for specific tumor types by combining genomics and current medicines," he said. "We feel this holds great promise for personalized cancer therapy."


'/>"/>

Contact: Jason Cody
codyja@msu.edu
517-432-0924
Michigan State University
Source:Eurekalert  

Related medicine news :

1. Penn researchers find new role for cancer protein p53
2. UCSF researchers uncover hormone pathway to fatty liver disease
3. Researchers pinpoint patients who receive greatest benefit from heart failure treatment
4. IDIBELL researchers discover a substance against the dark genome of cancer
5. Wayne State University researchers publish results settling multiple sclerosis debate
6. E-health must be a priority, researchers say
7. Mayo Clinic researchers confirm value of therapeutic hypothermia after cardiac arrest
8. Mayo researchers, Rochester educators, students to present at science conference
9. Researchers work at the frontiers of islet cell transplantation
10. Brain Appears to Be a Task Machine, Researchers Say
11. Researchers develop outline that may help weigh benefits of new imaging technologies
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers pinpoint genetic pathways involved in breast cancer
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced ... feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as a ... has released tools for healthy coping following a traumatic event. , Trauma sufferers tend ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are ... for this recognition are considered among the top 2 percent of lawyers practicing within ... of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, ...
(Date:6/24/2016)... TX (PRWEB) , ... June 24, 2016 , ... People ... part in Genome magazine’s Code Talker Award, an essay contest in which patients and ... an award to be presented at the 2016 National Society of Genetic Counselors (NSGC) ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Frederick area economy by obtaining investment capital for emerging technology companies. ... years that have already resulted in more than a million dollars of capital ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
(Date:6/24/2016)... , June 24, 2016 VolitionRx ... of Dr. Edward Futcher to the ... effective June 23, 2016.Dr. Futcher was also appointed ... Governance Committees.  As a non-executive member of the ... and strategic counsel to VolitionRx in connection with ...
Breaking Medicine Technology: